Expression profile of cord blood neutrophils and dysregulation of HSPA1A and OLR1 upon challenge by bacterial peptidoglycan.
Authors: Fong O, Chan K, Leung K, Lam H, Cheung H, Leung T, Li K, Ng P
J Leukoc Biol, 2014;95(1):169-78.
Species: Human
Sample Type: Cell Lysate
Application: IP
Altered sciatic nerve fiber morphology and endoneural microvessels in mouse models relevant for obesity, peripheral diabetic polyneuropathy, and the metabolic syndrome.
Authors: Nowicki M, Kosacka J, Serke H, Bluher M, Spanel-Borowski K
J. Neurosci. Res., 2012;90(1):122-31.
Species: Mouse
Sample Type: Tissue Homogenates
Application: WB
The variable expression of lectin-like oxidized low-density lipoprotein receptor (LOX-1) and signs of autophagy and apoptosis in freshly harvested human granulosa cells depend on gonadotropin dose, age, and body weight.
Authors: Vilser C, Hueller H, Nowicki M, Hmeidan FA, Blumenauer V, Spanel-Borowski K
Fertil. Steril., 2010;93(8):2706-15.
Species: Human
Sample Type: Cell Lysates
Application: WB
Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy.
Authors: Zhang L, Liu Y, Lu XT, Wu YL, Zhang C, Ji XP, Wang R, Liu CX, Feng JB, Jiang H, Xu XS, Zhao YX, Zhang Y
Am. J. Physiol. Heart Circ. Physiol., 2009;297(6):H2004-14.
Species: Rabbit
Sample Type: Whole Cells
Application: ICC

Lectin-like oxidized low-density-lipoprotein receptor-1 (LOX-1), also known as oxidized low-density-lipoprotein receptor-1 (OLR-1), is a type II transmembrane receptor belonging to the C-type lectin family (1). It also belongs to the functionally defined scavenger receptor (SR) superfamily, whose members share the common ability to bind and internalize modified forms of Low Density Lipoproteins (LDL) (2-4). LOX-1 is the first member of the class E scavenger receptor subfamily (SR-E). It binds and supports the internalization of multiple structurally unrelated macromolecules including oxidized LDL, advanced glycation end products (AGE), activated platelets, bacteria, apoptotic or aged cells, and heat shock proteins (5-7). LOX-1 has also been implicated as an intestinal receptor involved in the transcytosis of pancreatic bile salt-dependent lipase (8). The human LOX-1 gene encodes a 273 amino acid (aa) residue protein with a short N-terminal intracellular domain, a transmembrane domain, an extracellular stalk/neck region followed by a C-type lectin-like domain (CTLD) (1, 6). The CTLD, which is required for ligand recognition, contains the six conserved cysteine residues present in all C-type lectins, but lacks the Ca²⁺-binding residues found in classical C-type lectins. LOX-1 can be detected on activated endothelial cells, vascular smooth muscle cells, macrophages, intestinal cells, and dendritic cells (6-8). The expression of LOX-1 is induced by proinflammatory or proatherogenic stimuli, as well as by oxidized LDL itself and hemodynamic or oxidative stress. Human LOX-1 exists on the cell surface as covalent homodimers, which can further associate into non-covalent-linked oligomers (9). Cell surface LOX-1 can also be cleaved by yet unidentified proteases to release the soluble LOX-1 extracellular domain (6). Binding and endocytosis of oxidized LDL by LOX-1 induces oxidative stress, activates NF kappa B, and upregulates the expression of monocyte chemoattractant protein-1 and matrix metalloproteases (5-9). LOX-1-dependent oxidized LDL uptake also induces apoptosis by inducing the expression of the pro-apoptotic Bax and downregulation of the anti-apoptotic Bcl-2 (10). Oxidized LDL plays a key role in the pathogenesis of atherosclerosis and endothelial dysfunction. Blockade of LOX-1 functions may turn out to be a suitable target for the therapeutic intervention of atherosclerosis.

1. Sawamura, T. et al. (1997) Nature 386:73. 
2. Daugherty, A. et al. (2000) Curr. Opin. Cardiovasc. Pulm. Ren. Invest. Drugs. 2:223. 
3. Platt, N. and S. Gordon (2001) J. Clin. Invest. 108:649. 
4. Platt, N. and S. Gordon (1998) Chem. Biol. 5:R193. 
5. Jono, T. et al. (2002) FEBS Lett. 511:170. 
6. Kume, N. et al. (2001) Curr. Opin. Lipidol. 12:419.
7. Delneste, Y. et al. (2002) Immunity 17:353.
8. Bruneau, N. et al. (2003) Mol. Biol. Cell 14:2861.
9. Xie, Q. et al. (2004) DNA and Cell Biol. 23:111.
10. Chen, J. et al. (2003) Circ. Res. 94:370.